Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Thomas A. Werfel(University of Mississippi Medical Center), Craig L. Duvall(Vanderbilt University), Taylor E. Kavanaugh(Vanderbilt University), Linus Lee(Vanderbilt University), Paula I. González-Ericsson(Breast Cancer Research Foundation), Somtochukwu C. Dimobi(Vanderbilt University), Violeta Sánchez(Vanderbilt University), Donna J. Hicks(Vanderbilt University), Meghan M. Joly(UL Research Institutes), Samantha M. Sarett(Vanderbilt University), Shan Wang(Vanderbilt University Medical Center), Rebecca S. Cook(Vanderbilt University), Dana M. Brantley‐Sieders(Susan G. Komen Breast Cancer Foundation), Meredith A. Jackson(Vanderbilt University), Kameron V. Kilchrist(Vanderbilt University)
Cited by 82
Related Papers
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
|Journal of Clinical Investigation|2008|276
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
|The Journal of Pathology|2020|223